Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.

Balena R, Hensley IE, Miller S, Barnett AH.

Diabetes Obes Metab. 2013 Jun;15(6):485-502. doi: 10.1111/dom.12025. Epub 2012 Nov 12. Review.

2.

GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.

Porcellati F, Lucidi P, Bolli GB, Fanelli CG.

Diabetes Metab. 2015 Dec;41(6 Suppl 1):6S16-6S20. doi: 10.1016/S1262-3636(16)30004-0.

PMID:
26774015
3.

Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.

Holst JJ, Vilsbøll T.

Diabetes Obes Metab. 2013 Jan;15(1):3-14. doi: 10.1111/j.1463-1326.2012.01628.x. Epub 2012 Jun 29. Review.

PMID:
22646532
4.

Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?

Darmon P, Raccah D.

Diabetes Metab. 2015 Dec;41(6 Suppl 1):6S21-6S27. doi: 10.1016/S1262-3636(16)30005-2.

PMID:
26774016
5.

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.

Owens DR, Monnier L, Bolli GB.

Diabetes Metab. 2013 Dec;39(6):485-96. doi: 10.1016/j.diabet.2013.09.004. Epub 2013 Oct 22. Review.

PMID:
24156868
6.
7.

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Deacon CF, Mannucci E, Ahrén B.

Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Review.

PMID:
22471248
8.
9.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

10.

Is insulin the most effective injectable antihyperglycaemic therapy?

Buse JB, Peters A, Russell-Jones D, Furber S, Donsmark M, Han J, MacConell L, Maggs D, Diamant M.

Diabetes Obes Metab. 2015 Feb;17(2):145-51. doi: 10.1111/dom.12402. Epub 2014 Nov 9.

PMID:
25323312
11.

The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.

de Boer SA, Lefrandt JD, Petersen JF, Boersma HH, Mulder DJ, Hoogenberg K.

Int J Clin Pharm. 2016 Feb;38(1):144-51. doi: 10.1007/s11096-015-0219-8. Epub 2015 Nov 23.

12.

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy.

Tobin GS, Cavaghan MK, Hoogwerf BJ, McGill JB.

Int J Clin Pract. 2012 Dec;66(12):1147-57. doi: 10.1111/ijcp.12032. Epub 2012 Oct 14. Review.

13.

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

Karagiannis T, Liakos A, Bekiari E, Athanasiadou E, Paschos P, Vasilakou D, Mainou M, Rika M, Boura P, Matthews DR, Tsapas A.

Diabetes Obes Metab. 2015 Nov;17(11):1065-74. doi: 10.1111/dom.12541. Epub 2015 Sep 23. Review.

PMID:
26395850
14.

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.

Tzefos M, Harris K, Brackett A.

Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Review.

PMID:
22232377
15.

Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.

McCormack PL.

Drugs. 2014 Mar;74(3):325-51. doi: 10.1007/s40265-013-0172-6. Review.

PMID:
24435322
16.

Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.

Carris NW, Taylor JR, Gums JG.

Drugs. 2014 Dec;74(18):2141-52. doi: 10.1007/s40265-014-0325-2. Review.

PMID:
25414121
17.

The rationale for combining GLP-1 receptor agonists with basal insulin.

Cohen ND, Audehm R, Pretorius E, Kaye J, Chapman LH, Colagiuri S.

Med J Aust. 2013 Aug 19;199(4):246-9. Review.

PMID:
23984780
18.

Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.

Hirsch IB, Buse JB, Leahy J, McGill JB, Peters A, Rodbard HW, Rubin RR, Skyler JS, Verderese CA, Riddle MC.

Diabetes Obes Metab. 2014 Mar;16(3):206-14. doi: 10.1111/dom.12136. Epub 2013 Jun 20. Review.

PMID:
23711193
19.

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.

Ridge T, Moretto T, MacConell L, Pencek R, Han J, Schulteis C, Porter L.

Diabetes Obes Metab. 2012 Dec;14(12):1097-103. doi: 10.1111/j.1463-1326.2012.01639.x. Epub 2012 Jul 19.

20.

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, de Vries D, Hoogwerf BJ, MacConell L, Wolffenbuttel BH; 4B Study Group.

Diabetes Care. 2014 Oct;37(10):2763-73. doi: 10.2337/dc14-0876. Epub 2014 Jul 10.

PMID:
25011946

Supplemental Content

Support Center